- Home
- CIM vs TSHA Comparison
CIM vs TSHA Comparison
Compare CIM & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIM
- TSHA
- Stock Information
- Founded
- CIM 2007
- TSHA 2019
- Country
- CIM United States
- TSHA United States
- Employees
- CIM N/A
- TSHA 73
- Industry
- CIM Real Estate Investment Trusts
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CIM Real Estate
- TSHA Health Care
- Exchange
- CIM Nasdaq
- TSHA Nasdaq
- Market Cap
- CIM 1.0B
- TSHA 1.2B
- IPO Year
- CIM 2007
- TSHA 2020
- Fundamental
- Price
- CIM $12.28
- TSHA $4.47
- Analyst Decision
- CIM Buy
- TSHA Strong Buy
- Analyst Count
- CIM 3
- TSHA 9
- Target Price
- CIM $15.25
- TSHA $10.22
- AVG Volume (30 Days)
- CIM 828.2K
- TSHA 3.7M
- Earning Date
- CIM 11-06-2025
- TSHA 11-04-2025
- Dividend Yield
- CIM 12.16%
- TSHA N/A
- EPS Growth
- CIM N/A
- TSHA N/A
- EPS
- CIM N/A
- TSHA N/A
- Revenue
- CIM $191,573,000.00
- TSHA $6,310,000.00
- Revenue This Year
- CIM $18.13
- TSHA N/A
- Revenue Next Year
- CIM $17.95
- TSHA N/A
- P/E Ratio
- CIM N/A
- TSHA N/A
- Revenue Growth
- CIM N/A
- TSHA N/A
- 52 Week Low
- CIM $9.85
- TSHA $1.05
- 52 Week High
- CIM $15.37
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- CIM 47.93
- TSHA 54.28
- Support Level
- CIM $11.67
- TSHA $3.92
- Resistance Level
- CIM $12.24
- TSHA $4.34
- Average True Range (ATR)
- CIM 0.28
- TSHA 0.28
- MACD
- CIM 0.05
- TSHA 0.01
- Stochastic Oscillator
- CIM 76.48
- TSHA 93.14
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.